Condition: Alpha 1-Antitrypsin Deficiency · Emphysema or COPD · Sponsor: Columbia University
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous population, the most predominant genotype being PiMZ. The purpose of this study in PiMZ heterozygous patients is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers pertinent to the PiMZ patient that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.
This description comes directly from the study's public registry record.
Sabrina Palumbo, BS · 2123053745 · sp4461@cumc.columbia.edu
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Not Yet Recruiting |
| University of California- Los Angeles | Los Angeles, California, United States | Recruiting |
| National Jewish Health | Denver, Colorado, United States | Not Yet Recruiting |
| University of Chicago | Chicago, Illinois, United States | Not Yet Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06505603